Pavan Lall And Sohini Das

Stories by Pavan Lall And Sohini Das

Maruti Suzuki finds digital highway ideal for smooth drive

Maruti Suzuki finds digital highway ideal for smooth drive

Rediff.com   9 Jun 2021

Maruti is not an online outlier, of course; other heavyweights have rolled out similar services. But as an analyst pointed out, Maruti's all-India roll-out has significant impact given that it accounts for over half of all cars sold, reports, reports Pavan Lall.

COVID-19 Vaccine: 4 months from lab to jab

COVID-19 Vaccine: 4 months from lab to jab

Rediff.com   8 Jun 2021

'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'

Covishield produced more antibodies than Covaxin: Study

Covishield produced more antibodies than Covaxin: Study

Rediff.com   7 Jun 2021

The study by a group of doctors showed that after two shots of the vaccines, 98 per cent recipients of Covishield showed antibody response, while the same was 80 per cent among Covaxin recipients. Sohini Das and Ruchika Chitravanshi report.

Biological E inks deal with Canadian firm for mRNA Covid vaccine

Biological E inks deal with Canadian firm for mRNA Covid vaccine

Rediff.com   2 Jun 2021

Providence will sell up to 30 mn doses of its mRNA vaccine to Biological E. It would also provide the necessary technology transfer to make the vaccine in India, with a minimum production capacity of 600 mn doses in 2022 and targets capacity of 1 bn doses, reports Sohini Das.

Bharat Biotech to make 900 million Covaxin vaccines

Bharat Biotech to make 900 million Covaxin vaccines

Rediff.com   1 Jun 2021

500 million doses per annum from its two sites in Hyderabad and 200 million doses each from its Ankleshwar and Kolar facilities.

'EVs are the way forward for Volkswagen group'

'EVs are the way forward for Volkswagen group'

Rediff.com   1 Jun 2021

'Our strategy is intact and our important pillars for India -- the SUV roll-out and the focus on the cost of ownership of a car -- remain in focus'

DRDO's Covid drug: Benefits. Concerns

DRDO's Covid drug: Benefits. Concerns

Rediff.com   31 May 2021

Commercial launch and supply to major government and private hospitals is expected in mid-June.

Self-use Covid-19 testing kits to be available at stores for Rs 250

Self-use Covid-19 testing kits to be available at stores for Rs 250

Rediff.com   21 May 2021

Pune's Mylab Discovery Solutions' CoviSelf, which gives results in 15 minutes, gets ICMR nod

Cipla ready to partner in Covid vaccine distribution

Cipla ready to partner in Covid vaccine distribution

Rediff.com   17 May 2021

However, Cipla was very clear it does not want to get into vaccine manufacturing.

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Covaxin output scaled up to 500 million jabs a year: Bharat Biotech

Rediff.com   17 May 2021

This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.

Govt hopeful of vaccinating adult population by December

Govt hopeful of vaccinating adult population by December

Rediff.com   15 May 2021

India expects 2.16 billion doses of Covid-19 vaccines between August and December, including the jabs that are currently in clinical trials, reports Sohini Das

Private hospitals may import Covid vaccines

Private hospitals may import Covid vaccines

Rediff.com   15 May 2021

Apollo Hospitals and Fortis Healthcare are open to importing vaccines.

Prices of key Covid bulk drugs shoot up as demand rises

Prices of key Covid bulk drugs shoot up as demand rises

Rediff.com   12 May 2021

The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.

With Covid surge, FabiFlu becomes most sold drug in India

With Covid surge, FabiFlu becomes most sold drug in India

Rediff.com   11 May 2021

Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.

COVID-19 second wave: Delays in RT-PCR tests

COVID-19 second wave: Delays in RT-PCR tests

Rediff.com   9 May 2021

While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.

'No preparedness planning, no accountability, no action plan'

'No preparedness planning, no accountability, no action plan'

Rediff.com   8 May 2021

'This government did not have any plan for safety stocks of essential medicines.'

Pharma industry posts 51.5% growth in April sales

Pharma industry posts 51.5% growth in April sales

Rediff.com   8 May 2021

When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.

Remdesivir black-market thrives as Covid cases rise

Remdesivir black-market thrives as Covid cases rise

Rediff.com   6 May 2021

Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das

Gujarat gets lion's share of Covid vaccines

Gujarat gets lion's share of Covid vaccines

Rediff.com   4 May 2021

Delhi, which has been one of the worst affected states, accounted for less than two per cent of total vaccinations in the 18-44 age-group.

In India, luxury used car market is in the fast lane

In India, luxury used car market is in the fast lane

Rediff.com   1 May 2021

The new car market is estimated at around 30,000 units a year in sales in a good year, whereas the used car market for luxury vehicles is estimated at around 60,000 cars annually.